# GEOMETRY mono-1: capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer

Source: https://onco.cc/key-papers/paper-geometry-mono-1-capmatinib-nejm-2020/  
OnCo record `paper-geometry-mono-1-capmatinib-nejm-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The MET inhibitor capmatinib shrank tumours in two thirds of untreated and four in ten previously treated patients with MET exon 14-skipping lung cancer, leading to the first approval for this driver, while MET-amplified tumours responded only at very high copy number.

## Summary

Phase 2 multicohort study of 364 patients with advanced non-small-cell lung cancer with MET exon 14 skipping or MET amplification treated with capmatinib.

In exon 14-skipping disease, objective response was 68 percent in treatment-naive and 41 percent in previously treated patients, with median durations of 12.6 and 9.7 months; in MET-amplified disease, response was 40 percent only with gene copy number of 10 or more. Peripheral oedema and nausea were common.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: New England Journal of Medicine
- Year: 2020
- DOI: 10.1056/NEJMoa2002787
- Authors: Wolf J, Seto T, Han JY, et al.
- Findings: Exon 14 skipping: objective response 68 percent (treatment-naive) and 41 percent (previously treated).; MET amplification: response 40 percent at gene copy number 10 or more, low below that.
- What it means: MET exon 14 skipping is a standard target in lung cancer, tested by RNA-based methods, with capmatinib or tepotinib as first-line or later options.
- Caveats: Single-arm; peripheral oedema is frequent and can be dose limiting.; MET amplification without exon 14 skipping is a weaker target.

## Sources

- N Engl J Med 2020: https://doi.org/10.1056/NEJMoa2002787
- PubMed: https://pubmed.ncbi.nlm.nih.gov/32877583/

## Connected records

- cancers: [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/)
- drugs: [Capmatinib](https://onco.cc/drugs/capmatinib/)
- trials: [GEOMETRY mono-1](https://onco.cc/trials/geometry-mono-1/)
- journals: [New England Journal of Medicine](https://onco.cc/journals/nejm/)

---
JSON: https://onco.cc/api/v1/entities/paper-geometry-mono-1-capmatinib-nejm-2020.json